Volume 16, Issue 5 , Pages 533-539, September 2009
Aromatase Inhibitors: Potential Reproductive Implications
Abstract
MEDLINE, EMBASE, Scopus, and Web of Science databases literature search from inception to March 2009 was performed to identify published clinical trials and cohort, observational, and in vitro studies that evaluated the use of aromatase inhibitors in reproductive medicine for indications other than ovulation induction. Aromatase inhibitors are currently being investigated for breast cancer prevention in women at high risk. Aromatase inhibitors may be used for treatment of symptomatic myomas and endometriosis as an alternative to surgical intervention. Current evidence does not support the routine use of aromatase inhibitors for these conditions without prospective controlled trials. Aromatase inhibitor cotreatment can be used to prevent the initial estrogen flare effect of gonadotropin-releasing hormone agonist treatment to offer flexibility in initiating this therapy.
Keywords: Anastrazole, Aromatase inhibitors, Bone loss, Breast cancer, Endometriosis, Exemstane, GnRh antagonists and flare phenomenon, Hormone therapy, Intracrinology, Letrozole, Myomas
To access this article, please choose from the options below
The authors have no commercial, proprietary, or financial interest in the products or companies described in this article.
PII: S1553-4650(09)00250-7
doi:10.1016/j.jmig.2009.05.009
© 2009 AAGL. Published by Elsevier Inc. All rights reserved.
Volume 16, Issue 5 , Pages 533-539, September 2009
